

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/054,710		01/22/2002	Koichi Masuda	047940-0119	5419
23524	7590	04/27/2006		EXAM	INER
FOLEY &	LARDN	IER LLP	DAVIS, RUTH A		
150 EAST	GILMAN	STREET			
P.O. BOX 1497				ART UNIT	PAPER NUMBER
MADISON, WI 53701-1497				1651	
				D. TE MAN ED 04/05/000	

DATE MAILED: 04/27/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action

Application No.	Applicant(s)	
10/054,710	MASUDA ET AL.	
Examiner	Art Unit	
Ruth A. Davis	1651	

Before the Filing of an Appeal Brief --The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 18 April 2006 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. X The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires <u>3</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a)⊠ They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 112,1 and 2 of record. 6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. X For purposes of appeal, the proposed amendment(s): a) X will not be entered, or b) \, will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1-14,17-30 and 33-35. Claim(s) withdrawn from consideration: 15-16,31-32. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). 13. Other: See Continuation Sheet.

Continuation Sheet (PTOL-303)

Continuation of 3. NOTE: The proposed limitation of "measuring proteoglycan loss from engineered cartilage tissue at a time not more than 12 days from culturing" is considered new matter because the specification fails to identify such a step. The specification does teach measuring the proteoglycan content at 1, 2, 3 and 5 days from culture, however the specification fails to place a time limit of 12 days post culture, such that the proteoglycan content must be measured. Further, limiting the time by which one has to measure the proteoglycan content is a limitation that has not been previously searched. It is also noted that the requirment for measuring proteoglycan content without the use of a radioactive agent has not been searched, per se, since the limitation was previously presented as a trait of the cultured engineered tissue rather than as a step requird by the claimed method.

Continuation of 13. Other: Regarding applicant's arguments that the references do not teach the claimed culturing time, it is reiterated that Masuda does, in fact, teach the culture times as indicated in the previous office action. Regarding applicant's argument that the attributes are not inherent to the claimed method, the attributes to which applicant refers have been presented as traits of the cultured ECT, thus since the ECT of the prior art and the claimed ECT are cultured in the same manner, the ECTs are regarded as having the same intrinsic qualties (as stated in the previous office action). Finally, in response to applicant's request to point out where the reference teach the claimed limitations, it is noted that Purchio and Lansbury teach measuring proteoglycan content by way or staining (Purchio, col.16, Lansbury p.25) while Huch teaches measuring proteoglycan content after 3 days culture (p.2158).

RUTH A. DAVIS PATENT EXAMINE